CytRx Corporation (CYTR)

0.32
0.01 3.00
OTC
Prev Close 0.33
Open 0.32
Day Low/High 0.31 / 0.34
52 Wk Low/High 0.26 / 1.14
Volume 23.95K
Exchange OTC
Shares Outstanding 33.64B
Market Cap 10.77M
Div & Yield N.A. (N.A)
CytRx (CYTR) Is Strong On High Volume Today

CytRx (CYTR) Is Strong On High Volume Today

Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate

Interesting CYTR Put And Call Options For December 18th

Interesting CYTR Put And Call Options For December 18th

Investors in CytRx Corp saw new options begin trading this week, for the December 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation

CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation

Shares of CytRx (CYTR) were up in late afternoon trading Friday after Oppenheimer initiated coverage on the stock.

Strong On High Relative Volume: CytRx (CYTR)

Strong On High Relative Volume: CytRx (CYTR)

Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate

Bears Shouldn't Get Too Cocky

There's still plenty of action out there.

First Week of September 18th Options Trading For CYTR

First Week of September 18th Options Trading For CYTR

Investors in CytRx Corp saw new options begin trading this week, for the September 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.

Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws

Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws

The law firm of Federman & Sherwood has initiated an investigation into CytRx Corporation (NASDAQ: CYTR) with respect to possible violations of federal securities laws.

CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas

CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to...

CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference

CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & ...

CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas

CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

4 Under-$10 Biotech Stocks in Breakout Territory

4 Under-$10 Biotech Stocks in Breakout Territory

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty

Levi & Korsinsky, LLP is investigating CytRx Corporation (NASDAQ:CYTR) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.

Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology

Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its oral presentation given by Sant P.

CytRx Reports 2014 Second Quarter Financial Results

CytRx Reports 2014 Second Quarter Financial Results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended June 30, 2014, and also provided an overview of ...

CytRx Added To Russell 3000® And Russell 2000® Indexes

CytRx Added To Russell 3000® And Russell 2000® Indexes

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it was added to the Russell 3000 ® and Russell 2000 ® Indexes when the...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

5 Stocks Poised to Break Out

5 Stocks Poised to Break Out

These stocks look ready to break out and trade higher from current levels.

3 Stocks Under $10 Moving Higher

3 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

CytRx To Present At The Jefferies 2014 Global Healthcare Conference

CytRx To Present At The Jefferies 2014 Global Healthcare Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma

CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

3 Biotech Stocks Under $10 to Watch

3 Biotech Stocks Under $10 to Watch

Keep an eye on these under-$10 biotech stocks.

CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma

CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, presented updated progression-free survival (PFS) and overall survival (OS) results from its completed...

CytRx Reports 2014 First Quarter Financial Results

CytRx Reports 2014 First Quarter Financial Results

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 3 months ended March 31, 2014, and also provided an overview of...